Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PBM Psyence Biomedical Ltd

Trading 11-22 13:28:35 EST

0.0475

+0.0005

+1.06%

High0.0487	Low0.0425	Vol8.05M
Open0.0470	D1 Closing0.0470	Amplitude13.19%
Mkt Cap3.01M	Tradable Cap2.36M	Total Shares63.38M
T/O363.33K	T/O Rate16.20%	Tradable Shares49.71M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"PBM","market":"US","secType":"STK","nameCN":"Psyence Biomedical Ltd","latestPrice":0.0475,"timestamp":1732300111388,"preClose":0.047,"halted":0,"volume":8054314,"delay":0,"floatShares":49708600,"shares":63379563,"eps":-7.849832,"marketStatus":"Trading","change":0.0005,"latestTime":"11-22 13:28:35 EST","open":0.047,"high":0.0487,"low":0.0425,"amount":363327.720463056,"amplitude":0.131915,"askPrice":0.0476,"askSize":600,"bidPrice":0.0475,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-7.849832,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1732309200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.047,"preHourTrading":{"tag":"盘前","latestPrice":0.0458,"preClose":0.047,"latestTime":"09:26 EST","volume":2239998,"amount":104649.664642716,"timestamp":1732285603314},"postHourTrading":{"tag":"盘后","latestPrice":0.0435,"preClose":0.047,"latestTime":"19:57 EST","volume":362998,"amount":16306.4109,"timestamp":1732237077848},"volumeRatio":1.141531},"requestUrl":"/m/hq/s/PBM/tweets","defaultTab":"tweets","newsList":[{"id":"2484143448","title":"Psyence Biomedical gets extension to show compliance with Nasdaq’s listing rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2484143448","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484143448?lang=en_us&edition=fundamental","pubTime":"2024-11-20 22:52","pubTimestamp":1732114344,"startTime":"0","endTime":"0","summary":"Psyence Biomedical  has been granted an extension until Dec. 31, 2024 to demonstrate compliance with all Nasdaq continued listing rules. During the Nasdaq Listing Qualifications Hearing, Psyence Biomed presented a comprehensive plan to regain and maintain compliance with the exchange’s continued listing requirements, including 5550, the $1 minimum bid price requirement, 5550, the $1M minimum market value of publicly held shares requirement, and 5550, the $2.5 million minimum stockholders' equity requirement. As previously announced, the company will execute a 1-for-75 share consolidation that, when complete, will satisfy Nasdaq’s $1 minimum bid price requirement. It expects to demonstrate compliance with all the applicable rules for continued listing on The Nasdaq Capital Market within the panel’s extension.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4312025-psyence-biomedical-gets-extension-to-show-compliance-with-nasdaqs-listing-rules","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2484110347","title":"Psyence Biomedical Receives Nasdaq Extension to Meet Continued Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2484110347","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484110347?lang=en_us&edition=fundamental","pubTime":"2024-11-20 22:47","pubTimestamp":1732114074,"startTime":"0","endTime":"0","summary":"Psyence Biomedical (PBM) said Wednesday it has received extension from Nasdaq through Dec. 31 for demonstrating compliance with all continued listing requirements.During the hearing, the company provi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2210150020.SGD","MNQmain","QID","LU2210149790.SGD","TQQQ","NDAQ","IE00BGHQF748.EUR","BK4112","PBM","IE00B3QW5Z07.USD","PSQ","IE00B64PRP62.GBP","NQmain","QLD","SQQQ","BK4139","BK4585","LU2095319765.USD","BK4588",".IXIC","IE00BKPKM429.USD"],"gpt_icon":1},{"id":"2484118667","title":"BRIEF-Psyence Biomedical Announces Favorable Result Of Nasdaq Listing Qualifications Hearing","url":"https://stock-news.laohu8.com/highlight/detail?id=2484118667","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484118667?lang=en_us&edition=fundamental","pubTime":"2024-11-20 20:40","pubTimestamp":1732106408,"startTime":"0","endTime":"0","summary":"Nov 20 (Reuters) - Nasdaq Inc   :   * PSYENCE BIOMEDICAL ANNOUNCES FAVORABLE RESULT OF NASDAQ LISTING QUALIFICATIONS HEARING   * PSYENCE BIOMEDICAL LTD - NASDAQ GRANTS PSYENCE BIOMED EXTENSION UNTIL DECEMBER 31, 2024Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR",".IXIC","NDAQ","PSQ","BK4585","QLD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","LU2095319765.USD","SQQQ","IE00B64PRP62.GBP","TQQQ","BK4588","NQmain","IE00BKPKM429.USD","PBM","QID","MNQmain","BK4139"],"gpt_icon":0},{"id":"2484980190","title":"Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing","url":"https://stock-news.laohu8.com/highlight/detail?id=2484980190","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484980190?lang=en_us&edition=fundamental","pubTime":"2024-11-20 20:30","pubTimestamp":1732105800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUA7RVWB1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","LU2210150020.SGD","PBM","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210149790.SGD","BK4588","NDAQ","IE00BKPKM429.USD","BK4112"],"gpt_icon":0},{"id":"2484719012","title":"Psyence Biomedical Ltd - Nasdaq Grants Psyence Biomed Extension Until December 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2484719012","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484719012?lang=en_us&edition=fundamental","pubTime":"2024-11-20 20:30","pubTimestamp":1732105800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUA7RVWB1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","LU2095319765.USD","BK4588","LU2210149790.SGD","IE00B64PRP62.GBP","PBM","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BKPKM429.USD","BK4112","IE00B3QW5Z07.USD","NDAQ"],"gpt_icon":0},{"id":"2484904504","title":"BRIEF-Psyence Biomedical Announces Effective Date For 1-For-75 Share Consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2484904504","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484904504?lang=en_us&edition=fundamental","pubTime":"2024-11-20 06:19","pubTimestamp":1732054797,"startTime":"0","endTime":"0","summary":"Nov 19 (Reuters) - Psyence Biomedical Ltd   :   * PSYENCE BIOMEDICAL ANNOUNCES EFFECTIVE DATE FOR 1-FOR-75 SHARE CONSOLIDATIONSource text:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2484903145","title":"Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2484903145","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484903145?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:06","pubTimestamp":1732050378,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nFWN3MQ0TG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2484903141","title":"Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2484903141","media":"GlobeNewswire","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484903141?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:05","pubTimestamp":1732050300,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov. 19, 2024  -- Psyence Biomedical Ltd.   today announced an effective date for its previously-announced share consolidation. At its Annual General and Special Meeting of Shareholders, which was held on November 12, 2024, Psyence Biomed’s shareholders approved a consolidation of the Company’s common shares at a ratio of up to 1 common share for every 75 common shares held, with the final ratio to be determined by the Company’s board of directors . Also, as previously announced, the Board approved a 1-for-75 consolidation of its outstanding common shares.The Company's common shares will begin trading on a post-consolidated basis at the opening of the market on Tuesday, November 26, 2024. Following the consolidation, the Company's common shares will continue to trade under the symbol 'PBM' with the new CUSIP number 74449F209. The consolidation is part of the Company's plan to regain compliance with the minimum bid price requirement of Nasdaq Listing Rule 5450  for continued l","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NTgIdxqiLMziWZlqTH9KVQ--~B/aD04NTt3PTIwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/2b362d1b510647247b266a9002bacf8d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NTgIdxqiLMziWZlqTH9KVQ--~B/aD04NTt3PTIwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/2b362d1b510647247b266a9002bacf8d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psyence-biomedical-announces-effective-date-210500167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBM","SQQQ","TQQQ","PSQ","NQmain","MNQmain","PBMWW","QID","BK4139",".IXIC","QLD"],"gpt_icon":1},{"id":"2483061230","title":"Psyence Biomedical Announces Share Consolidation Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2483061230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483061230?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:47","pubTimestamp":1731451658,"startTime":"0","endTime":"0","summary":"Psyence Biomedical (PBM) has released an update. Psyence Biomedical announced key outcomes from its annual meeting, including the approval of a 75-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/psyence-biomedical-announces-share-consolidation-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/psyence-biomedical-announces-share-consolidation-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2483050507","title":"Psyence Biomedical Announces Results From Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination From Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2483050507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483050507?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:30","pubTimestamp":1731447000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nTUA2YFZDQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","NDAQ","IE00BGHQF748.EUR","BK4139","IE00B3QW5Z07.USD","BK4588","BK4585","IE00BKPKM429.USD","LU2095319765.USD","PBM","LU2210150020.SGD"],"gpt_icon":0},{"id":"2483505150","title":"Press Release: Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2483505150","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483505150?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:30","pubTimestamp":1731447000,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq. NEW YORK, Nov. 12, 2024  -- Psyence Biomedical Ltd.   today announced the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on November 12, 2024 .Shareholders were represented in person or by proxy at the meeting holding 21,877,200 common shares, representing approximately 43.5% of Psyence Biomed's 50,334,170 issued and outstanding common shares as of October 10, 2024, the record date for the Meeting. At the Meeting, a total of five resolutions  were submitted to and approved by the Company's shareholders. Each of the Proposals are described in detail in the Company's Management Information Circular filed as Exhibit 99.1 to the Current Report on Form 6-K filed by the Company with the U.S. Securities and Exchange Commission on October 23, 2024. The final results for the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","BK4588","QID","LU2413666699.HKD","LU2092937221.SGD","LU2210149790.SGD","LU2413666426.HKD","SQQQ","BK4567","LU0347712357.USD","BK4139","LU2210150020.SGD","BK4112","MNQmain","LU1721428933.USD",".IXIC","A","NDAQ","LU1543694498.USD","LU2095319765.USD","IE00BKPKM429.USD","LU2041044095.USD","BK4121","NQmain","LU1165135440.EUR","QLD","PBM","TQQQ","IE00B64PRP62.GBP","PSQ","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2481125152","title":"GoodRx Holdings Faces Sell Rating Amid PBM Pressure and Business Model Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2481125152","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481125152?lang=en_us&edition=fundamental","pubTime":"2024-11-08 17:48","pubTimestamp":1731059299,"startTime":"0","endTime":"0","summary":"Analyst Allen Lutz of Bank of America Securities reiterated a Sell rating on GoodRx Holdings (GDRX – Research Report), reducing the price target to...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/goodrx-holdings-faces-sell-rating-amid-pbm-pressure-and-business-model-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/goodrx-holdings-faces-sell-rating-amid-pbm-pressure-and-business-model-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PBM","GDRX"],"gpt_icon":0},{"id":"2481466602","title":"LTA to pilot blockchain-based conditional payments solution with OCBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2481466602","media":"Nurdianah Md Nur","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481466602?lang=en_us&edition=fundamental","pubTime":"2024-11-06 02:02","pubTimestamp":1730829769,"startTime":"0","endTime":"0","summary":"The move aims to digitally transform LTA’s disbursement of mobilisation advance payments to contractors.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/digitaledge/digital-economy/lta-pilot-blockchain-based-conditional-payments-solution-ocbc?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["SG9999002406.SGD","SG9999000475.SGD","LU0532188223.SGD","LU0821914370.USD","SG9999013486.USD","O39.SI","BK6523","FTVI","LU1048588211.SGD","SG9999004360.SGD","IE00B0169L03.USD","PBM","LU1130305938.SGD","SG9999006266.SGD","LU0251143029.SGD","LU1981816686.USD","LU1522347837.USD","LU0048573645.USD","SG9999001903.USD","LU1497733557.USD","BK4139","SG9999000327.SGD","LU0264606111.USD","LU1206713676.USD","SG9999008742.SGD","IE0031814969.USD","SG9999016042.SGD","LU0261945553.USD","LU0572940350.SGD","LU0737861269.HKD","LU1634259557.SGD","LU0210637038.USD","SG9999000343.SGD","SG9999000459.SGD","LU1206712785.SGD","SG9999003826.SGD","SG9999013478.USD","LU0955623706.USD","SG9999001689.USD","SG9999002414.USD","IE00B067MR52.USD","IE00B97KM107.HKD","LU1048596156.SGD","SG9999002679.SGD","SG9999005177.SGD","IE0032834883.USD","LU0181495838.USD","SG9999001135.SGD","IE0008368411.USD","BK6112"],"gpt_icon":1},{"id":"2481075335","title":"Grab and Ant International use stablecoin payment system by StraitsX for cross-border merchant payment settlement","url":"https://stock-news.laohu8.com/highlight/detail?id=2481075335","media":"Nicole Lim","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481075335?lang=en_us&edition=fundamental","pubTime":"2024-11-05 02:18","pubTimestamp":1730744318,"startTime":"0","endTime":"0","summary":"This stablecoin-powered payment system enables immediate Singapore dollar payment through the Singapore dollar-denominated regulated stablecoin.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/news/cryptocurrency/grab-and-ant-international-use-stablecoin-payment-system-straitsx-cross-border?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["BK4139","BABA","GRAB","PBM"],"gpt_icon":1},{"id":"2480585716","title":"Psyence Biomedical Acquires Stake in PsyLabs","url":"https://stock-news.laohu8.com/highlight/detail?id=2480585716","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480585716?lang=en_us&edition=fundamental","pubTime":"2024-11-02 04:32","pubTimestamp":1730493153,"startTime":"0","endTime":"0","summary":"Psyence Biomedical (PBM) has released an update. Psyence Biomedical has successfully closed its acquisition of Psyence Group’s stake in PsyLabs, en...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/psyence-biomedical-acquires-stake-in-psylabs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/psyence-biomedical-acquires-stake-in-psylabs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2480400990","title":"Decoding The Cigna Group (CI): A Strategic SWOT Insight","url":"https://stock-news.laohu8.com/highlight/detail?id=2480400990","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480400990?lang=en_us&edition=fundamental","pubTime":"2024-11-01 13:01","pubTimestamp":1730437300,"startTime":"0","endTime":"0","summary":"Weaknesses: Vulnerability to Market Fluctuations and Regulatory Changes.Opportunities: Expansion into Emerging Markets and Diversification of Services.On October 31, 2024, The Cigna Group  released its 10-Q filing, providing a detailed financial snapshot of the company's performance. The Cigna Group, a leader in pharmacy benefit management and health insurance services, reported a total revenue of $63.694 billion for the third quarter of 2024, a significant increase from $49.048 billion in the same period last year. However, net income for shareholders decreased to $739 million from $1.408 billion, indicating challenges that may impact profitability. This SWOT analysis delves into the strengths, weaknesses, opportunities, and threats as revealed by the latest financial data and market trends.Operational Costs and Expenses: The company's operational costs have risen, with pharmacy and other service costs increasing by 41% to $47.565 billion. This, coupled with medical costs and other be","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/J.JOrXYqaYD7_9CCqyNRbw--~B/aD0xNzk7dz00NTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/329f6cd64e5522368883f4e5e8bc1e9b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/J.JOrXYqaYD7_9CCqyNRbw--~B/aD0xNzk7dz00NTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/329f6cd64e5522368883f4e5e8bc1e9b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/decoding-cigna-group-ci-strategic-050140391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","IE0002270589.USD","IE00B19Z3B42.SGD","BK4585","LU0058720904.USD","LU1261432733.SGD","INAQU","IE00B19Z3581.USD","BK4139","BK4196","LU0289739699.SGD","LU0868494617.USD","PBM","CI","IE00BSNM7G36.USD","LU1059921491.USD"],"gpt_icon":0},{"id":"2480674056","title":"Psyence Group Closes Disposal of PsyLabs Stake; Shares Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2480674056","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480674056?lang=en_us&edition=fundamental","pubTime":"2024-11-01 00:26","pubTimestamp":1730392011,"startTime":"0","endTime":"0","summary":"Psyence Group said Thursday it has closed the disposal of its 11.13% stake in privately held PsyLabs to its associate, Psyence Biomedical .Psyence Biomedical will issue 2 million shares to Psyence Group as part of the deal, the company said.Additionally, Psyence Biomedical has issued 845,394 of its shares to Psyence Group following a debt-for-equity swap agreement, according to the statement.Shares of Psyence Biomedical plunged about 24% in recent trading.Price: 0.07, Change: -0.02, Percent Change: -24.47","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SES.SI","BK4139","PBM"],"gpt_icon":0},{"id":"2479078207","title":"Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in Psylabs","url":"https://stock-news.laohu8.com/highlight/detail?id=2479078207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479078207?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:30","pubTimestamp":1730374202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUA7TDYJF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2479218335","title":"Market Chatter: Celltrion's Zymfentra Gains Broad US Insurance Coverage with New PBM Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2479218335","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479218335?lang=en_us&edition=fundamental","pubTime":"2024-10-30 10:28","pubTimestamp":1730255321,"startTime":"0","endTime":"0","summary":"Celltrion  secured a listing for Zymfentra, its subcutaneous autoimmune treatment, on six major US insurance plans under one of the top three pharmacy benefit managers , Pulse News reported Tuesday.This inclusion boosts patient access by making Zymfentra, or infliximab-dyyb, eligible for insurance reimbursement across multiple networks, the report said.Approved by the US FDA in October 2023 and launched in March 2024, Zymfentra allows patients to self-administer infliximab at home. With this agreement, Zymfentra is now covered by over 90% of the US insurance market, it said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PBM","BK4139"],"gpt_icon":1},{"id":"2478933335","title":"Psyence Group's Nasdaq-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase Iib Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2478933335","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478933335?lang=en_us&edition=fundamental","pubTime":"2024-10-25 21:42","pubTimestamp":1729863720,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241025:nTUA7D3YWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pacificbooker.bc.ca","stockEarnings":[{"period":"1week","weight":-0.1296},{"period":"1month","weight":-0.5692},{"period":"3month","weight":-0.9069},{"period":"6month","weight":-0.9433},{"period":"1year","weight":-0.9968},{"period":"ytd","weight":-0.9949}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.261315},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.229033},{"month":3,"riseRate":1,"avgChangeRate":0.362272},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.067007},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.053855},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.193429},{"month":7,"riseRate":1,"avgChangeRate":0.326596},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.094421},{"month":9,"riseRate":0.666667,"avgChangeRate":-0.251038},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.101551},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.105765},{"month":12,"riseRate":0.5,"avgChangeRate":-0.086281}],"exchange":"NASDAQ","name":"Psyence Biomedical Ltd","nameEN":"Psyence Biomedical Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Psyence Biomedical Ltd(PBM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Psyence Biomedical Ltd,PBM,Psyence Biomedical Ltd股票,Psyence Biomedical Ltd股票老虎,Psyence Biomedical Ltd股票老虎国际,Psyence Biomedical Ltd行情,Psyence Biomedical Ltd股票行情,Psyence Biomedical Ltd股价,Psyence Biomedical Ltd股市,Psyence Biomedical Ltd股票价格,Psyence Biomedical Ltd股票交易,Psyence Biomedical Ltd股票购买,Psyence Biomedical Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Psyence Biomedical Ltd(PBM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction